SG11201707527YA - Inhibitors of hepatitis c virus polymerase - Google Patents

Inhibitors of hepatitis c virus polymerase

Info

Publication number
SG11201707527YA
SG11201707527YA SG11201707527YA SG11201707527YA SG11201707527YA SG 11201707527Y A SG11201707527Y A SG 11201707527YA SG 11201707527Y A SG11201707527Y A SG 11201707527YA SG 11201707527Y A SG11201707527Y A SG 11201707527YA SG 11201707527Y A SG11201707527Y A SG 11201707527YA
Authority
SG
Singapore
Prior art keywords
hepatitis
inhibitors
virus polymerase
polymerase
virus
Prior art date
Application number
SG11201707527YA
Other languages
English (en)
Inventor
Irina C Jacobson
Michael D Feese
Sam S Lee
Original Assignee
Cocrystal Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocrystal Pharma Inc filed Critical Cocrystal Pharma Inc
Publication of SG11201707527YA publication Critical patent/SG11201707527YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
SG11201707527YA 2015-03-23 2016-03-23 Inhibitors of hepatitis c virus polymerase SG11201707527YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562136857P 2015-03-23 2015-03-23
PCT/US2016/023664 WO2016154241A1 (en) 2015-03-23 2016-03-23 Inhibitors of hepatitis c virus polymerase

Publications (1)

Publication Number Publication Date
SG11201707527YA true SG11201707527YA (en) 2017-10-30

Family

ID=55759915

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201707527YA SG11201707527YA (en) 2015-03-23 2016-03-23 Inhibitors of hepatitis c virus polymerase

Country Status (18)

Country Link
US (2) US10464914B2 (https=)
EP (1) EP3274340B1 (https=)
JP (1) JP6741747B2 (https=)
KR (1) KR20170137113A (https=)
CN (1) CN107567442B (https=)
AU (1) AU2016235246B2 (https=)
CA (1) CA2979555C (https=)
DK (1) DK3274340T3 (https=)
EA (1) EA033622B1 (https=)
ES (1) ES2748974T3 (https=)
IL (1) IL254243B (https=)
MX (1) MX379015B (https=)
NZ (1) NZ735093A (https=)
PH (1) PH12017501687A1 (https=)
PL (1) PL3274340T3 (https=)
SG (1) SG11201707527YA (https=)
TW (1) TWI731854B (https=)
WO (1) WO2016154241A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI731854B (zh) * 2015-03-23 2021-07-01 美商共結晶製藥公司 C型肝炎病毒聚合酶之抑制劑
KR20210018806A (ko) * 2018-05-09 2021-02-18 코크리스탈 파마, 아이엔씨. Hcv의 치료를 위한 병용 요법
CN112745216A (zh) * 2019-10-30 2021-05-04 常州锐博生物科技有限公司 一种4-溴甲基苯甲酸甲酯及其衍生物的制备方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN114181187A (zh) * 2021-11-24 2022-03-15 上海应用技术大学 一种4-甲磺酰胺基丁酰胺化合物的制备方法
CN116283512B (zh) * 2023-02-24 2025-04-25 博诺康源(北京)药业科技有限公司 一种合成维兰特罗及其盐的方法
WO2025111414A1 (en) * 2023-11-21 2025-05-30 Katholieke Universiteit Leuven Trpm3-modulating benzofuran derivatives
CN119350612B (zh) * 2024-12-24 2025-10-24 浙江爱索拓标记医药科技有限公司 一种放射性同位素碳-14标记聚乙二醇单甲醚的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029075A1 (en) 1995-03-20 1996-09-26 Eli Lilly And Company 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
WO2002100846A1 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US6881741B2 (en) 2001-06-11 2005-04-19 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
DE60221627D1 (de) 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
EA009943B1 (ru) * 2002-11-01 2008-04-28 Вирофарма Инкорпорейтед Соединения бензофурана, композиции и способы лечения и профилактики инфекций, вызванных вирусом гепатита с, и связанных с ним заболеваний
KR101058696B1 (ko) 2002-12-10 2011-08-22 바이로켐 파마 인코포레이티드 후라비바이러스 감염의 치료 또는 예방을 위한 화합물과방법
US20040192707A1 (en) 2002-12-10 2004-09-30 Laval Chan Chun Kong Compounds and methods for the treatment or prevention of Flavivirus infections
MXPA05006196A (es) 2002-12-10 2006-01-27 Virochem Pharma Inc Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus.
US20070293484A1 (en) 2004-05-20 2007-12-20 Sugen, Inc. Thiophene Heteroaryl Amines
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
WO2006119646A1 (en) 2005-05-13 2006-11-16 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
PE20070814A1 (es) 2005-12-22 2007-08-16 Smithkline Beecham Corp Compuestos derivados de 2-carboxitiofeno como inhibidores de la polimerasa del virus de la hepatitis c (hcv)
WO2008017688A1 (en) 2006-08-11 2008-02-14 Smithkline Beecham Corporation 2-carboxy thiophene derivatives as anti-viral agents
TW200815384A (en) 2006-08-25 2008-04-01 Viropharma Inc Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
WO2008043791A2 (en) 2006-10-13 2008-04-17 Smithkline Beecham Corporation Thiophene derivatives for treating hepatitis c
JP5290186B2 (ja) 2006-11-15 2013-09-18 ヴァイロケム ファーマ インコーポレイテッド フラビウイルス感染症の治療または予防用のチオフェン類似体
US20090274655A1 (en) 2006-11-17 2009-11-05 Richard Martin Grimes 2-carboxy thiophene derivatives as anti viral agents
GB0707092D0 (en) 2007-04-12 2007-05-23 Smithkline Beecham Corp Compounds
GB0712393D0 (en) 2007-06-26 2007-08-01 Smithkline Beecham Corp Compounds
GB0718435D0 (en) * 2007-09-21 2007-10-31 Northern Health And Social Car Wpund care formulation
ATE539070T1 (de) 2008-02-14 2012-01-15 Hoffmann La Roche Heterozyklische antivirale verbindungen
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201136919A (en) * 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
AR082453A1 (es) * 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
AU2011329485A1 (en) * 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
US8771665B2 (en) 2010-12-17 2014-07-08 Cocrystal Discovery, Inc. Inhibitors of hepatitis C virus polymerase
WO2014055142A1 (en) 2012-06-20 2014-04-10 Cocrystal Discovery, Inc. Inhibitors of hepatitis c virus polymerase
TWI731854B (zh) * 2015-03-23 2021-07-01 美商共結晶製藥公司 C型肝炎病毒聚合酶之抑制劑

Also Published As

Publication number Publication date
PL3274340T3 (pl) 2020-01-31
CA2979555A1 (en) 2016-09-29
DK3274340T3 (da) 2019-10-07
IL254243B (en) 2020-10-29
HK1243703A1 (zh) 2018-07-20
CN107567442A (zh) 2018-01-09
EA033622B1 (ru) 2019-11-11
US20200255393A1 (en) 2020-08-13
CA2979555C (en) 2023-12-19
CN107567442B (zh) 2021-05-25
EP3274340B1 (en) 2019-07-17
IL254243A0 (en) 2017-10-31
EA201792094A1 (ru) 2018-03-30
US10464914B2 (en) 2019-11-05
EP3274340A1 (en) 2018-01-31
US20180050998A1 (en) 2018-02-22
MX2017012238A (es) 2018-02-15
KR20170137113A (ko) 2017-12-12
US10947210B2 (en) 2021-03-16
JP2018512453A (ja) 2018-05-17
ES2748974T3 (es) 2020-03-18
AU2016235246A1 (en) 2017-09-21
JP6741747B2 (ja) 2020-08-19
HK1249514A1 (en) 2018-11-02
AU2016235246B2 (en) 2020-12-10
NZ735093A (en) 2022-09-30
TWI731854B (zh) 2021-07-01
PH12017501687A1 (en) 2018-03-19
TW201643147A (zh) 2016-12-16
BR112017020168A2 (pt) 2018-06-05
MX379015B (es) 2025-03-10
WO2016154241A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
IL280459A (en) Phosphoramidates for the treatment of hepatitis b virus
IL251450A0 (en) Preparations and methods for silencing hepatitis b virus gene expression
SG11201707663SA (en) Lyophilization of rna
SG10202007323VA (en) Hepatitis b virus (hbv) irna compositions and methods of use thereof
SG11201803474UA (en) Vaccines against hepatitis b virus
IL254243B (en) Hepatitis C virus polymerase inhibitors.
IL247364A0 (en) c5a inhibitors for the treatment of viral pneumonia
SG10201913958QA (en) Modulation of hepatitis b virus replication
IL249660B (en) Methods for treating hepatitis b virus and hepatitis d virus infections
PL3137078T3 (pl) Leczenie zakażenia wirusem zapalenia wątroby typu delta
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
IL248318A0 (en) Selective inhibitors that have an effect on the hepatitis virus type c
GB201402169D0 (en) Viral inhibitors
TH1601001227A (th) ตัวยับยั้ง hcv โพลีเมอเรส
HK1234102A1 (en) Compositions and methods for silencing hepatitis b virus gene expression
GB201520019D0 (en) The genome and self-evolution of AI
GB201522013D0 (en) Virus
GB201416054D0 (en) Chemotherapy of viruses
GB201516936D0 (en) Virus
GB201507419D0 (en) Virus
GB201403369D0 (en) RNA Virus induced gene expression